ECEESPE2025 ePoster Presentations Pituitary, Neuroendocrinology and Puberty (220 abstracts)
A real-world study of lanreotide autogel for the treatment of patients with acromegaly in china: baseline interim analysis
Huijuan ZHU 1 , Ting Lei 2 , Yongjian Wang 3 , Wei Wang 4 , Lihui Zhang 5 , Zhipeng Su 6 , Zhongyan Shan 7 , Ping Li 8 , Yanbing Li 9 , Jun Yang 10 , Guijun Qing 11 , Huiling Chen 12 , Xiaoxi Pan 13 & Christelle Pommie 14
1Peking Union Medical College Hospital (PUMCH), Endocrinology, Beijing, China; 2Tongji Hospital, Tongji Medical College of HUST, Wuhan, China; 3The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China; 4West China Hospital, Chengdu, China; 5The Second hospital of Hebei Medical University, Shijiazhuang, China; 6The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; 7The First Hospital of China Medical University, Shenyang, China; 8Nanjing Drum Tower Hospital, Nanjing, China; 9The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; 10Peking University Third Hospital, Beijing, China; 11The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 12Xiangya Hospital Central South University, Changsha, China; 13Ipsen Pharma, Shanghai, China; 14Ipsen, Boulogne-Billancourt, France
JOINT2717
Objective: This real-world study (RWS) aims to evaluate the effectiveness, safety, and treatment patterns of lanreotide autogel (LAN) in Chinese patients with acromegaly. The abstract summarizes only baseline data.
Methods: This multicenter, prospective, observational real-world study was conducted across 12 sites in China. A total of 127 patients with acromegaly were planned to enroll based on key inclusion criteria: serum insulin-like growth factor-1 (IGF-1) levels above the upper limit of normal (ULN) and fasting growth hormone (GH) levels >2.5 µg/l, untreated with LAN. Fasting GH and IGF-1 levels, and LAN administration details (dose titration and interval adjustments), were collected at baseline (last before index), 3, 6, and 12 months after LAN initiation. Adverse events (AEs) and special situations (e.g., pregnancy, overdose) were monitored throughout the study. The baseline data include demographic, clinical characteristics (time since acromegaly first diagnosis, size of pituitary tumor, symptoms, comorbidities, etc.), and prior treatments for acromegaly (treatment types, prior medications, etc.). The primary endpoint is defined as the proportion of patients achieving biochemical control (fasting GH level ≤2.5 μg/land IGF-1 return to normal range adjusted to age category) at 12 months.
Results: A total of 129 patients were enrolled and treated, of whom 75 (58.1%) were female. At baseline, patients had mean (SD) age of 43.3 (13.4) years, body mass index of 25.97 (4.11) kg/m2, and fasting GH (µg/l)and IGF-1 (xULN) of 22.30 (49.15) and 2.10 (1.75), respectively. The median (95% CI) time to acromegaly first diagnosis was 1.1 (0.8, 1.7) years. Pituitary tumors were observed in 97/127 (76.4%) patients at baseline, with 50 (39.4%) macroadenomas and 29 (22.8%) microadenomas. Clinical symptoms were present in 112 (86.8%) patients (soft tissue swelling (63.6%), headache (39.5%), joint pain (29.5%), fatigue (27.1%), and excessive sweating (20.9%)). Comorbidities were observed in 81 (62.8%) patients (altered carbohydrate metabolism (27.1%), sleep apnea (26.4%), hypopituitarism (25.6%), hypertension (20.2%), and heart disease (12.4%)). 66.7% of the patients had undergone pituitary transsphenoidal surgery, 31.0% had radiotherapy, and 41.9% had prior medications (Octreotide LAR, 27.1%; Bromocriptine, 10.1%; and Cabergoline, 3.9%). At the first LAN prescription, 91.5% of patients received a 28-day dosing schedule, 48.8% were prescribed 90 mg and 51.2% for 120 mg.
Conclusions: This interim analysis shows the study mainly included postoperative patients with pituitary macroadenomas and multiple comorbidities. LAN was administered at doses of 90 mg and 120 mg half each, predominately once every 28 days in Chinese patients with acromegaly.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more